The next-generation antibodies market is one of the fastest-growing segments in the global next-generation biologics market, and is one of the major research area for biotechnology and pharmaceutical companies due to their wide application platform ranging from rare diseases to generic and chronic ones. Nowadays, the availability of antibodies ranges from oncology indications to autoimmune diseases as well as rare ones like hemophilia and cystic fibrosis. Since the launch of Orthoclone OKT3 (muromonab-CD3), the first antibody, in 1986, over 50 antibodies have been approved globally.In this report, Technavio covers the present scenario and growth prospects of the global next-generation biologics market for 2016-2020 (base year: 2015; forecast end year: 2020). To calculate the market size, the report considers revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.

PART 01: Executive summary 9

Highlights 9

PART 02: Scope of the report 11

Market overview 11

Top-vendor offerings 13

PART 03: Market research methodology 14

Research methodology 14

Economic indicators 14

PART 04: Introduction 15

Key market highlights 15

PART 05: Market landscape 17

Market overview 17

Five forces analysis 24

PART 06: Market segmentation by application 25

Global regenerative medicine market 27

Global next-generation antibodies market 36

Global next-generation insulin products market 41

Global next-generation recombinant coagulation factors market 44

PART 07: Geographical segmentation 48

Next-generation biologics market in Americas 50

Next-generation biologics market in EMEA 53

Next-generation biologics market in APAC 56

PART 08: Market drivers 60

Increase in demand for ADCs 60

Advanced technological innovations 61

Reimbursement support for next-generation biologics 64

Special regulatory drug designations for biologics 67

PART 09: Impact of drivers 70

PART 10: Market challenges 71

Complexities in manufacturing of biologics 71

Complicated regulatory framework 71

Difficulties in patient recruitment for conducting clinical trials, high cost, and failure rate in clinical trials 72

Critical ethical challenges in clinical trial design 73

PART 11: Impact of drivers and challenges 75

PART 12: Market trends 76

Focus on regenerative medicines 76

Focus on oral insulin therapies 81

Development of gene and cell therapy-based products 82

Emergence of targeted and combination therapies 84

PART 13: Vendor landscape 85

Competitive scenario 85

Key news 86

Other prominent vendors 90

PART 14: Key vendor analysis 105

Biogen 105

F. Hoffmann-La Roche 108

Novo Nordisk 113

Sanofi 115

Takeda Pharmaceuticals 118

PART 15: Appendix 121

List of abbreviations 121

PART 16: Explore Technavio 123